Principia Biopharma, which is developing oral small molecule therapies in the areas of oncology and immunology, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2008 and booked $29 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol PRNB. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
